Prime Highlights:
ADHD medication prescriptions have increased by 18% annually since the Covid-19 pandemic, according to a new study.
Research from the University of Huddersfield and Aston University reveals a significant rise in prescriptions across England.
Key background:
Prescriptions for medications used to treat attention deficit hyperactivity disorder (ADHD) have risen by 18% annually since the Covid-19 pandemic, according to a new study. The research, conducted by experts from the University of Huddersfield and Aston University, highlights a significant increase in the number of prescriptions for ADHD medications across England.
The study, published in BMJ Mental Health, examined prescribing data for five licensed ADHD medications, including methylphenidate (commonly known as Ritalin and Concerta), dexamphetamine, lisdexamfetamine, and non-stimulants such as atomoxetine and guanfacine. Findings revealed that prescriptions for these medications have surged from 25.17 per 1,000 population in 2019/20 to 41.55 in 2023/24, with an average annual increase of 18%.
Experts suggest that increased awareness of ADHD, particularly through social media, may contribute to the rise in diagnoses and subsequent treatment. However, they caution that misinformation on these platforms could lead to misconceptions about ADHD symptoms, diagnosis, and treatment. Another factor influencing the rise in prescriptions could be the impact of the Covid-19 pandemic, which worsened ADHD symptoms for many individuals. The study noted regional variations in prescription growth, with the London region seeing the highest increase at 28% annually, while the North East and Yorkshire region experienced a 13% rise.
Methylphenidate remained the most commonly prescribed ADHD medication, while lisdexamfetamine showed the most rapid growth in prescriptions, increasing by 55% annually. The study also underscored the benefits of ADHD medications, citing evidence that they improve quality of life, cognitive abilities, and reduce substance misuse. Dr. Ulrich Muller-Sedgwick, ADHD champion at the Royal College of Psychiatrists, emphasized the importance of timely and effective assessment for those with ADHD, as well as the need for targeted investment to expand ADHD services.
